ALS Awards for target discovery and therapy development
/TARGET ALS AWARDS SIX INNOVATIVE RESEARCH TEAMS WITH ADDITIONAL TARGET DISCOVERY FUNDS
New York City – Target ALS is pleased to announce that it has awarded target discovery and development funding to six research consortia that are working toward the development of ground-breaking therapeutic approaches to treating ALS.
In 2016 – 2017, Target ALS provided multi-year grants to a number of unique research consortia to encourage ALS research ideation and active involvement from both the pharma/biotech industry as well as the most talented new investigators in the field. In a historic first, either a pharma/biotech researcher or a new investigator led each team. These teams were awarded funding for a range of novel projects from early stage target discovery to the development of new therapeutic approaches.
A wave of creative thinking and collaboration followed. Indeed, many projects have led to the development of new, ground-breaking therapeutic approaches while others are advancing our understanding of pathophysiology of ALS. In response to this growing momentum, the Target ALS Independent Review Committee (IRC) granted six of the most promising collaborative projects an additional year of funding.
